Literature DB >> 17338624

Time course of nicotinamide adenine dinucleotide diaphorase staining after renal radiofrequency ablation influences viability assessment.

J Kyle Anderson1, Meredith Baker, Omar Jaffers, Margaret S Pearle, Guy L Lindberg, Jeffrey A Cadeddu.   

Abstract

BACKGROUND AND
PURPOSE: Nicotinamide adenine dinucleotide (NADH) diaphorase staining has been used to confirm cell viability or death after radiofrequency ablation (RFA) of renal tissue. The time course over which NADH staining status converts from viable to non-viable after a lethal insult has not been defined for renal RFA, but the change may not be immediate. Our objective was to assess porcine renal tissue for viability using NADH diaphorase staining at various times after RFA.
MATERIALS AND METHODS: Seven pigs underwent monopolar RFA of both kidneys followed by needle biopsy of the ablation zone before and immediately after ablation and at 15-minute intervals thereafter. Initially, a single kidney was treated, and the contralateral kidney was treated 2 weeks later. Biopsies were taken from untreated renal parenchyma in a similar time course after nephrectomy to examine the effect of ischemia. All biopsy specimens, as well as representative sections of the ablation zone, were subjected to NADH staining and reviewed by a pathologist who was blinded to the tissue treatment.
RESULTS: Most of the post-RFA biopsy specimens (86%) showed non-viable tissue. However, 14% of the specimens revealed viable tissue as late as 150 minutes after RFA. Therefore, none were positive. In the nephrectomy parenchyma, 92% of the biopsy specimens showed viable tissue as late as 4 hours after the onset of ischemia.
CONCLUSION: Staining for NADH can establish tissue non-viability after RFA, but the timing of staining after treatment must be considered when interpreting results to avoid false positive tests. Tissue that is apparently viable by NADH staining within 2.5 hours of RFA may in fact have been ablated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17338624     DOI: 10.1089/end.2005.1128

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  14 in total

1.  Loss of cellular viability in areas of ground-glass opacity on computed tomography images immediately after pulmonary radiofrequency ablation in rabbits.

Authors:  Masaomi Kuroki; Hiroshi Nakada; Atsushi Yamashita; Akira Sawaguchi; Noriko Uchino; Shinya Sato; Taketoshi Asanuma; Yujiro Asada; Shozo Tamura
Journal:  Jpn J Radiol       Date:  2012-05       Impact factor: 2.374

2.  High-powered microwave ablation of t1a renal cell carcinoma: safety and initial clinical evaluation.

Authors:  Anna J Moreland; Timothy J Ziemlewicz; Sara L Best; J Louis Hinshaw; Meghan G Lubner; Marci L Alexander; Christopher L Brace; Douglas R Kitchin; Sean P Hedican; Stephen Y Nakada; Fred T Lee; E Jason Abel
Journal:  J Endourol       Date:  2014-07-02       Impact factor: 2.942

3.  Chronological changes of radiofrequency ablation zone in rabbit liver: an in vivo correlation between gross pathology and histopathology.

Authors:  Kyoung D Song; Min Woo Lee; Hyunchul Rhim; Tae Wook Kang; Dong Ik Cha; Jehoon Yang
Journal:  Br J Radiol       Date:  2017-01-31       Impact factor: 3.039

4.  Management of renal tumors in Von Hippel-Lindau disease by percutaneous CT fluoroscopic guided radiofrequency ablation: preliminary results.

Authors:  Yoichi Iwamoto; Hideki Kanda; Koichiro Yamakado; Norihito Soga; Kiminobu Arima; Kan Takeda; Yoshiki Sugimura
Journal:  Fam Cancer       Date:  2011-09       Impact factor: 2.375

5.  Real-time monitoring of radiofrequency ablation and postablation assessment: accuracy of contrast-enhanced US in experimental rat liver model.

Authors:  Hanping Wu; Luke R Wilkins; Nicholas P Ziats; John R Haaga; Agata A Exner
Journal:  Radiology       Date:  2013-10-28       Impact factor: 11.105

6.  Radiofrequency ablation of renal tumours with clinical, radiographical and pathological results.

Authors:  Jose A Karam; Kamran Ahrar; Raghunandan Vikram; Claudio A Romero; Eric Jonasch; Nizar M Tannir; Priya Rao; Christopher G Wood; Surena F Matin
Journal:  BJU Int       Date:  2013-03-19       Impact factor: 5.588

7.  Gas-filled phospholipid nanoparticles conjugated with gadolinium play a role as a potential theragnostics for MR-guided HIFU ablation.

Authors:  Se-Young Choi; Young-Sun Kim; Yeong-Ju Seo; Jehoon Yang; Kyu-Sil Choi
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

8.  Quantitative Multi-Parametric Magnetic Resonance Imaging of Tumor Response to Photodynamic Therapy.

Authors:  Tom J L Schreurs; Stefanie J Hectors; Igor Jacobs; Holger Grüll; Klaas Nicolay; Gustav J Strijkers
Journal:  PLoS One       Date:  2016-11-07       Impact factor: 3.240

9.  Procedural sedation and analgesia for respiratory-gated MR-HIFU in the liver: a feasibility study.

Authors:  Johanna M M van Breugel; Joost W Wijlemans; Hermanus H B Vaessen; Martijn de Greef; Chrit T W Moonen; Maurice A A J van den Bosch; Mario G Ries
Journal:  J Ther Ultrasound       Date:  2016-07-29

10.  Radiofrequency ablation: a minimally invasive approach in kidney tumor management.

Authors:  Maciej Salagierski; Marek S Salagierski
Journal:  Cancers (Basel)       Date:  2010-11-17       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.